These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 28791708)
1. Exosomal DNMT1 mediates cisplatin resistance in ovarian cancer. Cao YL; Zhuang T; Xing BH; Li N; Li Q Cell Biochem Funct; 2017 Aug; 35(6):296-303. PubMed ID: 28791708 [TBL] [Abstract][Full Text] [Related]
2. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422 [TBL] [Abstract][Full Text] [Related]
3. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Yang YI; Kim JH; Lee KT; Choi JH Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308 [TBL] [Abstract][Full Text] [Related]
4. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer]. Qi C; Zhang QH; Li JX Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111 [TBL] [Abstract][Full Text] [Related]
5. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. Sui C; Meng F; Li Y; Jiang Y J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928 [TBL] [Abstract][Full Text] [Related]
6. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2. Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Dorayappan KDP; Wanner R; Wallbillich JJ; Saini U; Zingarelli R; Suarez AA; Cohn DE; Selvendiran K Oncogene; 2018 Jul; 37(28):3806-3821. PubMed ID: 29636548 [TBL] [Abstract][Full Text] [Related]
8. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Ma JJ; Chen BL; Xin XY Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744 [TBL] [Abstract][Full Text] [Related]
9. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. Wang H; Luo Y; Qiao T; Wu Z; Huang Z J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003 [TBL] [Abstract][Full Text] [Related]
10. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound. Yu T; Yang Y; Zhang J; He H; Ren X Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779 [TBL] [Abstract][Full Text] [Related]
11. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1. Shang X; Lin X; Manorek G; Howell SB Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666 [TBL] [Abstract][Full Text] [Related]
12. Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo. Shen Y; Ren ML; Shi YH; Zhang YX; Cai YL Eur J Gynaecol Oncol; 2012; 33(6):584-90. PubMed ID: 23327050 [TBL] [Abstract][Full Text] [Related]
13. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer. Tang XH; Li M; Deng S; Lu MS Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341 [TBL] [Abstract][Full Text] [Related]
14. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. Cacan E J Chemother; 2017 Jun; 29(3):173-178. PubMed ID: 28102109 [TBL] [Abstract][Full Text] [Related]
16. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. Shen W; Liang B; Yin J; Li X; Cheng J Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462 [TBL] [Abstract][Full Text] [Related]
17. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558 [TBL] [Abstract][Full Text] [Related]
18. Exploiting mechanoregulation via FAK/YAP to overcome platinum resistance in ovarian cancer. Dang LN; Choi J; Lee E; Lim Y; Kwon JW; Park S Biomed Pharmacother; 2024 Oct; 179():117335. PubMed ID: 39191020 [TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
20. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1. Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]